{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:59Z","timestamp":1794315419913,"version":"4.9.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:56:31Z","timestamp":1775620591000},"page":"100152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of major organ involvement in Beh\u00e7et syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-4715","authenticated-orcid":false,"given":"Yesim","family":"Ozguler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem Nihal","family":"Esatoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5810","authenticated-orcid":false,"given":"Vladimira","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-0311","authenticated-orcid":false,"given":"Omar","family":"Dhrif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-0604","authenticated-orcid":false,"given":"Georgina","family":"Ducker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-6861","authenticated-orcid":false,"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-005X","authenticated-orcid":false,"given":"Ina","family":"Koetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Moots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-9611","authenticated-orcid":false,"given":"Aleksandra","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-453X","authenticated-orcid":false,"given":"Ilknur","family":"Tugal-Tutkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Uygunoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0001","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.ero.2026.02.019_bib0002","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","article-title":"Mortality in Behcet's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Behcet syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.ero.2026.02.019_bib0004","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2026.02.019_bib0005","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ero.2026.02.019_bib0006","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0007","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","article-title":"Management of skin, mucosa and joint involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"48","author":"Leccese","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ero.2026.02.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ero.2026.02.017","article-title":"Management of mucocutaneous and joint involvement of Beh\u00e7et\u2019s syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations","author":"Esatoglu","year":"2026","journal-title":"EULAR Rheumatology Open"},{"key":"10.1016\/j.ero.2026.02.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.02.009","article-title":"2025 update of the EULAR Recommendations for the Management of Beh\u00e7et\u2019s Syndrome","author":"Hatemi","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2026.02.019_bib0010","unstructured":"EULAR SOPs\u2014Standard Operating Procedures for Task Forces 2025. Accessed June 25, 2025. Available from: https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/1288\/44fd21f5-69ff-449e-a959-c1398468bfe1\/1198."},{"key":"10.1016\/j.ero.2026.02.019_bib0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ero.2026.02.019_bib0012","article-title":"Management of Beh\u00e7et\u2019s syndrome: a systematic review to inform the update of the EULAR recommendations","author":"Ozguler","year":"2024","journal-title":"PROSPERO"},{"key":"10.1016\/j.ero.2026.02.019_bib0013","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ero.2026.02.019_bib0014","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.ero.2026.02.019_bib0015","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1016\/S2665-9913(24)00194-2","article-title":"Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behcet\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial","volume":"6","author":"Zhong","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0016","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/rheumatology\/keae585","article-title":"Infliximab vs interferon-alpha in the treatment of Behcet\u2019s syndrome: clinical data from the BIO-BEHCET\u2019s randomized controlled trial","volume":"64","author":"Moots","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.ero.2026.02.019_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699903","article-title":"Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-A when combined with glucocorticoid in the treatment of refractory Behcet\u2019s uveitis: a randomized controlled prospective study","volume":"12","author":"Qian","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.ero.2026.02.019_bib0018","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1756-185X.13095","article-title":"High-dose intravenous steroid pulse therapy in ocular involvement of Behcet\u2019s disease: a pilot double-blind controlled study","volume":"20","author":"Mohammadi","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"10.1016\/j.ero.2026.02.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300354","article-title":"Infliximab versus cyclophosphamide for severe Behcet\u2019s syndrome","volume":"3","author":"Saadoun","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ero.2026.02.019_bib0020","article-title":"The efficacy of adalimumab as an initial treatment in patients with Behcet\u2019s retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ero.2026.02.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107430","article-title":"Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behcet\u2019s uveitis with vasculitis","volume":"93","author":"Yang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ero.2026.02.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease: multicenter study of 49 patients","volume":"58","author":"Barroso-Garcia","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.ero.2026.02.019_bib0023","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.3390\/jcm13237388","article-title":"Comparative study of adalimumab, infliximab and certolizumab Pegol in the treatment of cystoid macular edema due to Behcet\u2019s disease","volume":"13","author":"Barroso-Garcia","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ero.2026.02.019_bib0024","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet\u2019s disease: national multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.ero.2026.02.019_bib0025","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.4103\/IJO.IJO_2011_23","article-title":"Comparative results of use and switching of anti-TNF-alpha agents in adult Behcet\u2019s uveitis","volume":"72","author":"Mesen","year":"2024","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","article-title":"Anti-TNF-alpha therapy for refractory uveitis associated with Behcet\u2019s syndrome and sarcoidosis: a single center study of 131 patients","volume":"30","author":"Kunimi","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ero.2026.02.019_bib0027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09273948.2019.1606256","article-title":"Comparison of the treatment results for Behcet uveitis in patients treated with infliximab and interferon","volume":"28","author":"Yalcindag","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.ero.2026.02.019_bib0028","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09273948.2020.1815797","article-title":"Effectiveness of infliximab and interferon alpha-2a for the treatment of Behcet\u2019s uveitis: customizing therapy according to the clinical features","volume":"30","author":"De Simone","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.ero.2026.02.019_bib0029","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","article-title":"Predictors of sustained clinical response in patients with Behcet\u2019s disease-related uveitis treated with infliximab and adalimumab","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2026.02.019_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1095423","article-title":"Ten-year follow-up of infliximab treatment for uveitis in Behcet disease patients: a multicenter retrospective study","volume":"10","author":"Takeuchi","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.ero.2026.02.019_bib0032","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behcet\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","article-title":"Clinical course of acute deep vein thrombosis of the legs in Behcet\u2019s syndrome","volume":"59","author":"Ozguler","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.ero.2026.02.019_bib0034","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1756-185X.13778","article-title":"Efficacy of TNFalpha inhibitors for refractory vascular Behcet\u2019s disease: a multicenter observational study of 27 patients and a review of the literature","volume":"23","author":"Aksoy","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2026.02.019_bib0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1708538120927701","article-title":"Infliximab treatment in refractory vascular Behcet\u2019s disease: a single-center experience","volume":"28","author":"Kehribar","year":"2020","journal-title":"Vascular"},{"key":"10.1016\/j.ero.2026.02.019_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109682","article-title":"Infliximab for vascular involvement in Behcet\u2019s syndrome","volume":"253","author":"Hatemi","year":"2023","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.ero.2026.02.019_bib0037","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1007\/s10067-021-05748-x","article-title":"Clinical characteristics of pulmonary artery involvement in patients with Behcet\u2019s syndrome: single-centre experience of 61 patients","volume":"40","author":"Eroglu","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2026.02.019_bib0038","first-page":"575","article-title":"Evaluation of clinical features and treatment responses in cardiac and vascular involvement of Behcet\u2019s disease","volume":"15","author":"Yadigaroglu","year":"2024","journal-title":"Ann Clin Anal Med"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0039","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/10815589241232368","article-title":"Does anticoagulation in combination with immunosuppressive therapy prevent recurrent thrombosis in Behcet\u2019s disease?","volume":"72","author":"Erol","year":"2024","journal-title":"J Investig Med"},{"issue":"8","key":"10.1016\/j.ero.2026.02.019_bib0040","first-page":"1491","article-title":"Vascular Behcet\u2019s disease: a comparative study from Turkey and France","volume":"40","author":"Alibaz-Oner","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102783","article-title":"Direct oral anticoagulant for venous thrombosis in Behcet\u2019s syndrome","volume":"20","author":"Vautier","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ero.2026.02.019_bib0042","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jvsv.2021.02.007","article-title":"Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet\u2019s disease","volume":"9","author":"Aksoy","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"3","key":"10.1016\/j.ero.2026.02.019_bib0043","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jvsv.2016.01.003","article-title":"Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behcet\u2019s disease","volume":"4","author":"Alibaz-Oner","year":"2016","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"8","key":"10.1016\/j.ero.2026.02.019_bib0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/RHU.0000000000002137","article-title":"Anticoagulant treatment may decrease the relapse rate of pulmonary arterial involvement in Behcet\u2019s disease","volume":"30","author":"Abacar","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2026.02.019_bib0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jvs.2016.08.109","article-title":"The value of endografts in the surgical management of arterial lesions secondary to Behcet disease","volume":"65","author":"Yin","year":"2017","journal-title":"J Vasc Surg"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0046","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.surg.2015.11.022","article-title":"Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Behcet disease","volume":"159","author":"Liu","year":"2016","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0047","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jvs.2020.01.076","article-title":"Factors influencing the recurrence of arterial involvement after surgical repair in Behcet disease","volume":"72","author":"Gaudric","year":"2020","journal-title":"J Vasc Surg"},{"issue":"3","key":"10.1016\/j.ero.2026.02.019_bib0048","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5217\/ir.2020.00013","article-title":"Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet\u2019s disease: results from a large real-world observational study","volume":"19","author":"Suzuki","year":"2021","journal-title":"Intest Res"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0049","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1136\/annrheumdis-2020-219810","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Behcet\u2019s syndrome","volume":"82","author":"Zou","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2026.02.019_bib0051","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3899\/jrheum.221106","article-title":"Tocilizumab in Behcet disease: a multicenter study of 30 patients","volume":"50","author":"Khitri","year":"2023","journal-title":"J Rheumatol"},{"issue":"Suppl 132(5)","key":"10.1016\/j.ero.2026.02.019_bib0052","doi-asserted-by":"crossref","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Behcet\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0053","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/jovr.jovr_254_15","article-title":"Characteristics of macular edema in Behcet disease after intravitreal bevacizumab injection","volume":"12","author":"Ghassemi","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.ero.2026.02.019_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109633","article-title":"Intravitreal dexamethasone implants facilitate the management of refractory Behcet's uveitis with vasculitis","volume":"251","author":"Tao","year":"2023","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.ero.2026.02.019_bib0055","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet\u2019s disease: a safety and efficacy clinical study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ero.2026.02.019_bib0056","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","article-title":"Monthly intravitreal infliximab in Behcet\u2019s disease active posterior uveitis: a long-term safety study","volume":"41","author":"Refaat","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.ero.2026.02.019_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109298","article-title":"Baricitinib for the treatment of refractory vascular Behcet\u2019s disease","volume":"250","author":"Wang","year":"2023","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.ero.2026.02.019_bib0058","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","article-title":"Efficacy and safety of tocilizumab in Behcet\u2019s syndrome with refractory arterial lesions: a single-centre observational cohort study in China","volume":"61","author":"Zhong","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.ero.2026.02.019_bib0059","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221111285","article-title":"Effectiveness and safety of low-dose interferon alpha-2a treatment in Behcet\u2019s syndrome with refractory vascular or neurological involvement: a case series","volume":"13","author":"Sun","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.ero.2026.02.019_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet\u2019s disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0061","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5336\/cardiosci.2018-63041","article-title":"The use of pharmacomechanical thrombolytic treatment in deep vein thrombosis associated with Behcet\u2019s disease: one-year results","volume":"31","author":"Arslan UC","year":"2019","journal-title":"Turkiye Klinikleri Cardiovascular Sciences"},{"issue":"6","key":"10.1016\/j.ero.2026.02.019_bib0062","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","article-title":"Behcet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0063","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-019-1933-8","article-title":"Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet\u2019s disease","volume":"21","author":"Miyagawa","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0064","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3904\/kjim.2022.394","article-title":"Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet\u2019s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study","volume":"38","author":"Lee","year":"2023","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12876-023-03090-x","article-title":"Effectiveness and safety of adalimumab in patients with intestinal Behcet\u2019s disease: a real-world prospective observational study in South Korea","volume":"23","author":"Yu","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.ero.2026.02.019_bib0066","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","article-title":"Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s disease in the open label study following a phase 3 clinical trial","volume":"15","author":"Inoue","year":"2017","journal-title":"Intest Res"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0067","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5009\/gnl220278","article-title":"Efficacy and safety of infliximab in intestinal Behcet\u2019s disease: a multicenter, phase 3 study (BEGIN)","volume":"17","author":"Cheon","year":"2023","journal-title":"Gut Liver"},{"issue":"24","key":"10.1016\/j.ero.2026.02.019_bib0068","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ero.2026.02.019_bib0069","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/mr\/roab127","article-title":"Predictors of infliximab refractory intestinal Behcet\u2019s syndrome: a retrospective cohort study from the Shanghai Behcet\u2019s syndrome database","volume":"33","author":"Bao","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2026.02.019_bib0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","article-title":"Long-term outcomes and predictors of sustained response in patients with intestinal Behcet\u2019s disease treated with infliximab","volume":"62","author":"Zou","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.ero.2026.02.019_bib0071","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/jgh.14690","article-title":"Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behcet\u2019s disease","volume":"34","author":"Kinoshita","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ero.2026.02.019_bib0072","doi-asserted-by":"crossref","first-page":"otac017","DOI":"10.1093\/crocol\/otac017","article-title":"Efficacy of calcineurin Inhibitors for Induction of Remission in Intestinal Behcet\u2019s Disease","volume":"4","author":"Kawaguchi","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.ero.2026.02.019_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221124014","article-title":"Tofacitinib as an alternative therapy for refractory intestinal Behcet\u2019s syndrome","volume":"14","author":"Zou","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ero.2026.02.019_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Behcet\u2019s disease: a pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0075","article-title":"Long term efficacy and safety analysis of thalidomide monotherapy in the maintenance treatment of intestinal Behcet\u2032s disease","volume":"7","author":"Zhaopeng","year":"2023","journal-title":"Chin J Inflamm Bowel Dis"},{"issue":"23","key":"10.1016\/j.ero.2026.02.019_bib0076","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNFalpha in severe and refractory neuro-Behcet disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.ero.2026.02.019_bib0077","first-page":"2040","article-title":"Infliximab for parenchymal neuro-Behcet\u2019s syndrome: case series and meta-analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2026.02.019_bib0078","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/1756-185X.14209","article-title":"Infliximab therapy in parenchymal neuro-Behcet\u2019s disease: a single-center experience","volume":"24","author":"Yalcin Kehribar","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0079","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Behcet disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ero.2026.02.019_bib0080","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s10067-024-07118-9","article-title":"Long-term outcomes of infliximab treatment in neuro-Behcet syndrome: a single-center retrospective study","volume":"43","author":"Rabia","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.02.019_bib0081","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2169\/internalmedicine.1969-23","article-title":"Effect of infliximab on chronic progressive neuro-Behcet\u2019s disease: influence of the timing of introduction on the patient outcome","volume":"63","author":"Hirohata","year":"2024","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.ero.2026.02.019_bib0082","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3899\/jrheum.200300","article-title":"Long-term follow-up and optimization of infliximab in refractory uveitis due to Behcet disease: National Study of 103 White patients","volume":"48","author":"Martin-Varillas","year":"2021","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2026.02.019_bib0083","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Behcet\u2019s disease","volume":"125","author":"Martin-Varillas","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ero.2026.02.019_bib0084","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.40235","article-title":"Brief report: drug-free long-term remission in severe Behcet\u2019s disease following withdrawal of successful anti-tumor necrosis factor treatment","volume":"69","author":"Sfikakis","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2026.02.019_bib0085","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet\u2019s syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"20","key":"10.1016\/j.ero.2026.02.019_bib0086","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Behcet\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ero.2026.02.019_bib0087","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Behcet\u2019s syndrome","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:17:43Z","timestamp":1790900263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050708126000364"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.02.019","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of major organ involvement in Beh\u00e7et syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100152"}}